The Non-Financial Ledger

Trust is the foundation of the relationship between a pet owner and a veterinarian. That trust extends to the pharmaceutical companies that supply the treatments. Cathy Hartney trusted that system when her veterinarian prescribed Librela for her poodle mix, Jake, who was suffering from osteoarthritis. The drug was marketed as a safe and effective way to manage his pain. The reality, as detailed in legal filings, was a nightmare.

Within days of his first injection on May 16, 2024, Jake began a rapid decline. He experienced increased thirst, loss of appetite, and drastically limited mobility. He became unable to get up, soiling himself where he lay. His pain appeared to worsen. The treatment meant to improve his quality of life destroyed it. Faced with Jake’s dire condition, Hartney had to make the decision every pet owner dreads: humane euthanasia.

“Plaintiff was harmed economically by the loss of her pet, and also suffered extreme emotional stress and anguish from losing her beloved Jake.”

The cost of the injection was $181.50. The cost of losing a family member is incalculable. Hartney’s story is not an isolated incident. It is the lead example in a class-action complaint that seeks to represent thousands of others who purchased a product they believed was safe, only to watch their companions suffer.

Legal Receipts

The class-action complaint, case number 2:24-cv-9698 in the U.S. District Court for the District of New Jersey, lays out a damning timeline of alleged corporate negligence. The filing is blunt about the harm caused and Zoetis’s role in it.

(From Paragraph 1) “Librela has been associated with thousands of reported adverse events in dogs including lethargy, drooling, shaking, behavior changes, hiding, urinary incontinence, inappetence, increased or decreased thirst, ataxia, hind-end weakness, inability to walk, new or worsening seizures, organ damage, worsening osteoarthritis symptoms, worsening pain, and even death.”

(From Paragraph 3) “Defendant Zoetis, Inc., (‘Defendant’), the manufacturer of Librela, failed to adequately inform consumers (pet owners) about the dangers of Librela and misled consumers by representing that Librela is safe for use in dogs when it is not.”

(From Paragraph 41) “There is currently no antidote should a dog experience a significant adverse event after administration of Librela, although the drug is designed to exert an effect for a full month.”

Societal Impact Mapping

Animal Health Crisis

Librela belongs to a class of drugs targeting Nerve Growth Factor (NGF). The lawsuit points out that development of NGF inhibitors for humans was paused by the FDA in 2011 due to evidence linking them to worsening joint damage. In 2021, pharmaceutical giants Eli Lilly and Pfizer stopped development of a similar human drug after regulators rejected it. Yet, Zoetis moved forward with a version for pets.

The consequences, according to reports filed with regulators, have been severe. The FDA received over 3,800 reports of side effects by the end of 2023. The European Medicines Agency received over 12,300 reports since 2021. These numbers likely underrepresent the true scale, as not every incident is reported.

Economic Exploitation

With $8.54 billion in annual revenue (2023), Zoetis is the world’s largest animal-health company. The lawsuit alleges that this financial success is built, in part, on a foundation of misrepresentation. By marketing Librela as safe and effective, Zoetis captured a significant market of pet owners desperate to relieve their animals’ suffering. The lawsuit claims these consumers did not receive the benefit of their bargain. They purchased a product that, for many, caused more harm than good, leaving them with additional vet bills, end-of-life costs, and profound emotional distress, while the corporation booked the profits.

The “Cost of a Life” Metric

Corporate Science Under The Microscope

The claims of Librela’s safety and efficacy rest primarily on two company-sponsored studies: Corral (2021) and Krautmann (2021). The lawsuit highlights that an independent academic review of these studies found significant issues.

A 2023 report by Dr. Katrin Kronenberger, published in the journal Veterinary Evidence, detailed a list of “methodological flaws.” The Corral study’s authors were all employees of Zoetis. The Krautmann study had eleven of its thirteen authors employed by Zoetis. Dr. Kronenberger’s critique pointed to incomplete blinding of researchers, small sample sizes that were further reduced during the trial, and unexplained removal of certain dogs from the study. These flaws, the lawsuit implies, undermine the very foundation of Zoetis’s safety claims.

“These violations are especially concerning from a public health perspective because the promotional communications create a misleading impression regarding the effectiveness of Librela…”
– FDA Warning Letter to Zoetis, Nov. 20, 2023

This critique is bolstered by a formal warning letter from the FDA’s Center of Veterinary Medicine sent to Zoetis on November 20, 2023. The agency stated that the Librela website “made false or misleading claims about the efficacy of Librela,” and as a result, the product was misbranded in violation of federal law.

What Now?

The legal system is one avenue for accountability. Grassroots action is another. Here is what you need to know and what you can do.

Corporate Watchlist

• Zoetis, Inc.: The manufacturer and marketer of Librela. The company continues to stand by the drug’s safety “when used according to the label,” despite the thousands of adverse reports and the ongoing class-action lawsuit.

Regulatory Watchlist

• FDA Center for Veterinary Medicine (CVM): The body responsible for regulating animal drugs. They issued a warning but have not recalled the product. Continued public reporting of adverse events is crucial for their data collection and potential future action.

Resistance and Mutual Aid

• Report Adverse Events: If your pet has had a negative reaction to any medication, file an adverse event report with the FDA. This data is critical for holding corporations and regulators accountable.
• Support the Class Action: The lawsuit (Hartney v. Zoetis, Inc., Case No. 2:24-cv-9698) seeks to represent all persons in the United States whose pets suffered harm after a Librela injection. Follow its progress and share the information within your community.
• Organize Locally: Connect with other pet owners online and in your community. Sharing stories and information builds collective power and can prevent others from experiencing the same tragedy. Demand transparency from veterinarians about the full range of known side effects for any long-acting medication.